Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
CAMBRIDGE, Mass., March 05, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Cowen and Company 38th Annual Health Care Conference
Monday, March 12, 2018 at 12:00 p.m. ET in Boston, MA
Barclays Global Healthcare Conference
Wednesday, March 14, 2018 at 2:35 p.m. ET in Miami, FL
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
